{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:04:49Z","timestamp":1790726689586,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jid.2021.06.009","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:47:46Z","timestamp":1625788066000},"page":"235-239.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pityriasis Rubra Pilaris Response to IL-17A Inhibition Is Associated with IL-17C and CCL20 Protein Levels"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-9089","authenticated-orcid":false,"given":"Jennifer L.","family":"Strunck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-3394","authenticated-orcid":false,"given":"Brett","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-3159","authenticated-orcid":false,"given":"Barik","family":"Rajpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4307-593X","authenticated-orcid":false,"given":"Gail","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-8196","authenticated-orcid":false,"given":"Dylan","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4428-8889","authenticated-orcid":false,"given":"Christina A.","family":"Topham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-9269","authenticated-orcid":false,"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5188-2571","authenticated-orcid":false,"given":"Doris","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-1995","authenticated-orcid":false,"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4179-6629","authenticated-orcid":false,"given":"Yuangang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4310-9554","authenticated-orcid":false,"given":"Pamela","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0028-8986","authenticated-orcid":false,"given":"Teri M.","family":"Greiling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.06.009_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000346640","article-title":"Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition","volume":"226","author":"Adnot-Desanlis","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2021.06.009_bib2","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1111\/ajd.13215","article-title":"Successful treatment of pityriasis rubra pilaris with brodalumab","volume":"61","author":"De Rosa","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jid.2021.06.009_bib3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaad.2019.01.061","article-title":"Pityriasis rubra pilaris: a study evaluating patient quality of life in 2 populations","volume":"81","author":"Eastham","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.06.009_bib4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1684\/ejd.2019.3641","article-title":"Treatment of pityriasis rubra pilaris type I: a systematic review","volume":"29","author":"Engelmann","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jid.2021.06.009_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/bjd.12799","article-title":"Increased epidermal expression and absence of mutations in CARD14 in a series of patients with sporadic pityriasis rubra pilaris","volume":"170","author":"Eytan","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.06.009_bib6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamadermatol.2016.5384","article-title":"Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris","volume":"153","author":"Feldmeyer","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.06.009_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajhg.2012.05.010","article-title":"Familial pityriasis rubra pilaris is caused by mutations in CARD14","volume":"91","author":"Fuchs-Telem","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jid.2021.06.009_bib8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1468-3083.2009.03511.x","article-title":"Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series","volume":"24","author":"Garcovich","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.06.009_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.06.009_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.06.009_bib11","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.06.009_bib12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamadermatol.2020.0932","article-title":"Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial","volume":"156","author":"Haynes","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.06.009_bib13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.4049\/jimmunol.176.3.1431","article-title":"Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2","volume":"176","author":"Johansen","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.06.009_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.06.009_bib15","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.4049\/jimmunol.1201505","article-title":"Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation","volume":"190","author":"Johnston","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2021.06.009_bib16","first-page":"243","article-title":"Systemic therapies of pityriasis rubra pilaris: a systematic review","volume":"17","author":"Kromer","year":"2019","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jid.2021.06.009_bib17","doi-asserted-by":"crossref","first-page":"e13060","DOI":"10.1111\/dth.13060","article-title":"Patient experiences with biologics and apremilast in pityriasis rubra pilaris: a patient survey","volume":"32","author":"Maloney","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2021.06.009_bib18","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jid.2018.03.1525","article-title":"CARD14 gain-of-function mutation alone is sufficient to drive IL-23\/IL-17-mediated psoriasiform skin inflammation in\u00a0vivo","volume":"138","author":"Mellett","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"Suppl. 5","key":"10.1016\/j.jid.2021.06.009_bib19","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaad.2008.05.037","article-title":"Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy","volume":"59","author":"M\u00fcller","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.06.009_bib20","doi-asserted-by":"crossref","first-page":"e14403","DOI":"10.1111\/dth.14403","article-title":"Successful treatment of pityriasis rubra pilaris with guselkumab: serum CCL20 as a potential marker for the disease activity","volume":"33","author":"Nagai","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2021.06.009_bib21","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ni.2156","article-title":"IL-17C regulates the innate immune function of epithelial cells in an autocrine manner","volume":"12","author":"Ramirez-Carrozzi","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2021.06.009_bib22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2016.0091","article-title":"Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients","volume":"152","author":"Ross","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.06.009_bib23","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jid.2018.01.036","article-title":"Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis","volume":"138","author":"Vandeghinste","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.06.009_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.immuni.2018.05.012","article-title":"Gain-of-function mutation of Card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A","volume":"49","author":"Wang","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2021.06.009_bib25","doi-asserted-by":"crossref","first-page":"15750","DOI":"10.1038\/s41598-018-34054-x","article-title":"The roles of IL-17C in T cell-dependent and -independent inflammatory diseases","volume":"8","author":"Yamaguchi","year":"2018","journal-title":"Sci Rep"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21014159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21014159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:25:38Z","timestamp":1758302738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21014159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0022202X21014159"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.06.009","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pityriasis Rubra Pilaris Response to IL-17A Inhibition Is Associated with IL-17C and CCL20 Protein Levels","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}